Technological enhancements in peptide discovery and synthesis are emerging to meet the increasing number of incidences of cardiovascular and metabolic diseases. However, targeted delivery of peptide drugs within the therapeutic range remains a significant challenge for the biopharmaceutical industry. Parenteral administration—including intravenous, subcutaneous, and intramuscular injection—remains the primary method for commercialized therapeutic peptides.
From a patient perspective, oral administration is a preferred drug delivery method, providing improved patient compliance and facilitating outpatient therapy for chronic indications. Non-invasive delivery methods such as oral administration have increased over the past five years through the innovation efforts at start-up and big pharma companies. Indeed, the September 2019 approval of Rybelsus, (semaglutide) from Novo Nordisk is seen as a game changer within the industry as it allows oral delivery of high molecular weight (>1300 MW) peptide delivery.
This webcast will cover the physicochemical requirements for peptides and biological oral delivery barriers. Both aspects are crucial to de-risk pharmaceutical development and increase the success rate of first-in-human trials using innovative approaches.
Key Learning Objectives:
Who Should Attend:
For questions please contact Martha Devia: firstname.lastname@example.org